GSK to Invest $30bn in US R&D and Supply Chain Over Five Years

In a bold move to advance its presence in the United States, healthcare giant GSK has announced plans to channel $30 billion into research, development, and supply chain enhancements over the next five years. This significant investment underscores GSK's commitment to innovation in the biotech sector.

As part of this initiative, GSK is allocating $1.2 billion towards the creation of advanced manufacturing facilities and the integration of AI and cutting-edge digital technologies. These developments aim to foster the growth of new biopharmaceutical factories and laboratories.

Collaboration is key in GSK's strategy, as it works closely with industrial and medical gas providers to support its manufacturing efforts in cell and gene therapy products. Additionally, gases play a critical role in some GSK products, such as serving as propellants in inhalers.

Environmental sustainability is a pivotal element of GSK's future plans, focusing on reducing greenhouse gas emissions throughout its operations. The company has set an ambitious goal to utilize 100% renewable electricity by the year 2030, aiming to minimize its environmental footprint.

Medical gases are becoming increasingly important within healthcare settings, particularly as advancements in medical technologies and the demand for superior gas solutions surge. To explore how the industry is adapting to these changes while ensuring safety and efficiency, consider joining our upcoming webinar.

For an in-depth analysis, access the 2025 US healthcare report by clicking here.